Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Targeting Technologies

Full company profile

uuid00078hj

Namestring
Molecular Targeting Technologies
Legal namestring
Molecular Targeting Technologies, Inc.
Websiteurl
mtarget.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Molecular Targeting Technologies, Inc. (MTTI) is a privately held specialty life-sciences reagent company founded around 2012 and headquartered in West Chester, Pennsylvania. The company develops, manufactures, and sells molecular imaging agents — fluorescent probes, radiopharmaceuticals, lipophilic dyes, and phosphatidylserine- and phosphatidylethanolamine-targeting compounds — to biomedical researchers. Its portfolio is organized around branded platforms: CellVue® (fluorescent cell membrane labeling kits, licensed-in technology), NeuroVue® (lipophilic far-red filter-based dyes for neural tract tracing, licensed from PTI Research), PSVue® (Zn-DPA–based anionic membrane probes), SRfluor® 680 (squaraine rotaxane dyes), and complementary lines including Lipophilic Cyanines, Immobilized Steroid Beads for affinity chromatography, Duramycin-based apoptosis probes with Kd of 4–6 nM, cyclic RGD and 2-DG optical imaging agents, and Glucarate-Kit/OsteoVue radiopharmaceutical precursors.

The company distributes most products directly through an e-commerce storefront at mtarget.com to academic laboratories, research institutions, and biotechnology and pharmaceutical companies, with unit pricing generally between $250 and $700 and quote-based pricing for custom chemistry services. Approximately 1–10 employees operate from a single West Chester office. MTTI holds exclusive license and sublicense rights to the NeuroVue® and CellVue® brands and several patents covering core chemistries. Leadership includes CEO Dr. Chris Pak (former Centocor/J&J radiopharmaceutical inventor, 20 prior IND filings) and CMO Dr. Danielle Meyrick (radiotheranostics executive with prior CMO roles at ITM Oncologic, Telix Pharmaceuticals, AdvanCell, and GenesisCare CRO). The firm has additionally launched the EvaThera sub-brand (EvaThera.com) to extend toward clinical-stage imaging agents and presented clinical data on the PRRT candidate EBTATE at SNMMI 2026, signaling a strategic move beyond catalog reagents.

Revenue is generated primarily through one-time catalog purchases of research reagents and contract-based custom synthesis services, with no disclosed institutional funding or revenue figures. MTTI has received regional recognition including 2019 Ernst & Young Entrepreneur of the Year finalist status (Greater Philadelphia) and a Ben Franklin Emerging Business Award.

Short descriptiontext

Molecular Targeting Technologies is a privately held specialty life-sciences reagent company that develops and sells fluorescent probes, lipophilic dyes, radiopharmaceutical precursors, and imaging agents (CellVue®, NeuroVue®, PSVue®, SRfluor®, Duramycin products) to academic researchers and biotechnology companies through its mtarget.com e-commerce storefront and custom chemistry services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWest Chester, United States
HQ citystring
West Chester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescent imaging probes, molecular imaging reagents, radiopharmaceutical agents, cell labeling dyes, bioconjugation reagents
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Life Sciences Research Reagents
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Products Sales
TypeOne Time License
Description

MTTI generates revenue through direct sales of fluorescent probes, imaging agents, cell membrane labels, and related biochemical products to research institutions, academic laboratories, and biotechnology companies. Products are sold through an e-commerce platform with pricing ranging from approximately $250 to $700 per unit depending on the product type and size.

mtarget.com
2Custom Chemistry Services
TypeProfessional Services
Description

The company offers custom synthesis and chemistry services for specialized research needs, including custom affinity absorbents for chromatography, ligand affinity binding studies, and protein-ligand complexes for crystallography.

mtarget.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1Standard Research Products
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products priced per unit: Duramycin-NODAGA conjugate $256.00; Cyclic RGD products (CyAL-5 cRGD, Cy3 cRGD, cRGD-LC-fluorescein) $408.00 each; PSVue products range $340-$607; SRfluor products $373-$700; Tracer-653 $490.00; Glucarate-Kit $450.00; NeuroVue filters $493-$538; Immobilized Steroid Beads $468-$525 per mL; CellVue kits Mini $290-$304, Midi $455-$482, Maxi $1110-$1166; SANH crosslinker $294-$489; Cyanine Dyes $313-$357.

mtarget.com
2Custom Services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom Affinity Absorbents and custom chemistry services require contacting sales (briangray@mtarget.com) for pricing. Contact-based pricing model for custom projects.

mtarget.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CellVue®
Description

Fluorescent cell membrane labeling kits for tracking cell division and membrane staining

mtarget.com
+4 more records
Core offering1 text field

Molecular Targeting Technologies (MTTI) develops, manufactures, and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for life sciences research. Its catalog spans branded product lines such as CellVue® (cell membrane labels), NeuroVue® (neural tract tracing dyes), PSVue® (phosphatidylserine-targeting probes), SRfluor® (squaraine rotaxane dyes), duramycin-based phosphatidylethanolamine probes, cyclic RGD peptides, radiopharmaceutical cold kits, and immobilized steroid beads, alongside custom chemistry services for specialized reagent synthesis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 99mTc-glucarate cold kit formulation for radiopharmaceutical preparation
+1 more record
Product overview1 text field

Molecular Targeting Technologies is a life sciences reagent company that develops and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for research applications. The product portfolio includes branded product lines: CellVue® (cell membrane labeling kits), NeuroVue® (neural tract tracing dyes), PSVue® (anionic membrane-targeting fluorescent probes), and SRfluor® 680 (squaraine rotaxane dyes), alongside complementary product families of Lipophilic Cyanines, Immobilized Steroid Beads, Duramycin-based apoptosis labels, Optical Imaging Agents (including cyclic RGD peptides and cancer-targeting agents), Click Chemistry Reagents, Crosslinkers, and Dyes for Bioconjugation. The company also offers Custom Chemistry Services for specialized synthesis. These products serve researchers in molecular imaging, cell biology, neuroscience, and drug discovery applications.

Product and service11 records
1CellVue®
CategoryCell Membrane Labels
Description

Fluorescent cell membrane labeling kits that stably label lipid regions of cell membranes; available in multiple spectral variants (Maroon, Claret, Plum, Burgundy, Lavender, Lilac, Red, Jade, NIR780, NIR815) for cell tracking and membrane staining research.

2NeuroVue®
CategoryNeural Tract Tracing Dyes
Description

Lipophilic far-red emitting filter-based dyes for neural tract tracing studies; available in Maroon, Red, Orange, Burgundy, Jade, and Red Plus variants with tract tracing durations spanning 3 days to 3-4 weeks. Licensed from PTI Research, Inc.

3PSVue®
CategoryTargeted Fluorescent Probes
Description

Fluorescent probes with Zn-DPA targeting moiety that bind anionic membranes, including phosphatidylserine-targeting variants for apoptosis and microbial detection. Available in PSVue 380, 480, 550, 643, 794, Biotin, Control, and 499-WS (mSEEK) formulations.

4Lipophilic Cyanines
CategoryCell Membrane Dyes
Description

DiI and DiO series of lipophilic carbocyanine dyes for cell membrane staining, available in various alkyl chain lengths (C2 to C28) with spectral properties spanning excitation/emission from 480/499nm to 748/780nm.

5Immobilized Steroid Beads
CategoryAffinity Chromatography
Description

Sepharose 4FF beads with immobilized steroid ligands (Estradiol, Nortestosterone, Dexamethasone, Androstan, Long Spacer Arm Dexamethasone, and custom options) for affinity chromatography, ligand binding studies, and protein-ligand complex crystallization.

6Duramycin Products
CategoryApoptosis Labels
Description

Phosphatidylethanolamine (PE) binding agents including Duramycin and fluorescent conjugates (Cy3, Cy5, Cy7, Fluorescein, LC-Fluorescein, LC-Biotin, NODAGA). Duramycin binds PE with Kd of 4-6 nM at 1:1 ratio with exclusive specificity; NODAGA conjugate supports Ga-68 and Cu-64 radiolabeling for PET imaging.

7Optical Imaging Agents
CategoryOptical Imaging Agents
Description

Fluorescence imaging agents including cyclic RGD peptides for integrin targeting (CyAL-5 cRGD, Cy3 cRGD, cRGD-LC-fluorescein), CyAL-5 2-Deoxyglucose for cancer targeting, and Tracer-653 for vascular imaging.

8SRfluor® 680
CategoryCell Membrane Labels
Description

Lipophilic squaraine rotaxane far-red emitting dyes that accumulate at lipophilic sites inside living cells; available in Phenyl, azide, and Micellar Phenyl formulations for in vitro and in vivo applications.

9Click Chemistry Reagents
CategoryClick Chemistry Reagents
Description

Reagents for click chemistry reactions including crosslinkers used for bioconjugation and labeling applications.

10Crosslinkers
CategoryCrosslinkers
Description

Heterobifunctional linkers such as SANH (Succinimidyl 6-hydrazinonicotinate acetone hydrazone) used to introduce protected hydrazinonicotinimide functional groups into proteins, peptides, and surfaces.

11Dyes for Bioconjugation
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1PTI Research, Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

MTTI operates under license and sublicense agreements with PTI Research, Inc. for NeuroVue® and CellVue® products. These are core product lines for the company. The NeuroVue® brand is a trademark of PTI Research used under license, and CellVue® products are sold under sublicense from PTI Research, Inc.

mtarget.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Click Chemistry Tools sells heterobifunctional crosslinkers, click chemistry reagents, and bioconjugation dyes — directly overlapping with MTTI's Crosslinkers (SANH) and Dyes for Bioconjugation categories, and addressing the same research customer.

TypeDirect peer
Description

LI-COR is well known for IRDye infrared fluorescent dyes used in Western blots, microscopy, and in vivo imaging. Its IRDye platform competes directly with MTTI's NIR fluorescent probes (NIR780, NIR815) for near-infrared imaging research applications.

TypeDirect peer
Description

Biotium develops fluorescent probes and dyes for cell biology, neuroscience, and live-cell imaging — including membrane, nuclear, and organelle stains. The product overlap with CellVue®, PSVue®, and SRfluor® is tight, especially in fluorescent cell labeling kits sold via e-commerce.

TypeDirect peer
Description

Vector Laboratories develops labeling and detection reagents (immunohistochemistry, immunofluorescence, biotin-streptavidin systems) for research and clinical use. Its labeling reagent portfolio complements MTTI's Dyes for Bioconjugation and PSVue® Biotin products.

TypeBroad incumbent
Description

Thermo Fisher's Molecular Probes / Invitrogen catalog is the gold-standard research fluorescent reagent brand, offering membrane stains, nuclear stains, and labeling kits across the same research applications MTTI targets. It represents the dominant competitive force in catalog research fluorescent reagents.

6ATTO-Tec GmbH
TypeDirect peer
Description

ATTO-Tec specializes in high-performance fluorescent labels (ATTO series) used in microscopy, flow cytometry, and single-molecule imaging. Their labeling chemistries and spectral breadth directly compete with MTTI's lipophilic cyanines and CellVue® spectral variants.

TypeDirect peer
Description

AnaSpec provides fluorescent peptides, custom peptide synthesis, and bioconjugation reagents — overlapping with MTTI's Custom Chemistry Services and Cyclic RGD Imaging Agents. Their custom synthesis offering is the most directly comparable service business.

TypeDirect peer
Description

Cytodiagnostics manufactures lipid-based and gold nanoparticle imaging/labeling reagents including DiI/DiO analogs and custom surface functionalization. Its lipid membrane probe range directly competes with MTTI's Lipophilic Cyanines and PSVue® anionic membrane probes.

9Lumiprobe Corporation
TypeDirect peer
Description

Lumiprobe manufactures and sells a broad catalog of fluorescent dyes and labeling reagents for biomedical research, including cyanines, NHS esters, and specialty imaging probes. Its catalog scope and direct e-commerce model mirror MTTI's research products business most directly.

TypeBroad incumbent
Description

Revvity (formerly PerkinElmer Life Sciences) is a broad incumbent offering fluorescent imaging agents, radiopharmaceuticals, and preclinical imaging reagents through its Life Sciences portfolio. It competes with MTTI in optical imaging agents and radiopharmaceutical chemistry with much broader geographic reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Targeting Technologies

Life Sciences Research Reagentsmtarget.com

Molecular Targeting Technologies is a privately held specialty life-sciences reagent company that develops and sells fluorescent probes, lipophilic dyes, radiopharmaceutical precursors, and imaging agents (CellVue®, NeuroVue®, PSVue®, SRfluor®, Duramycin products) to academic researchers and biotechnology companies through its mtarget.com e-commerce storefront and custom chemistry services.

What Molecular Targeting Technologies does

Molecular Targeting Technologies, Inc. (MTTI) is a privately held specialty life-sciences reagent company founded around 2012 and headquartered in West Chester, Pennsylvania. The company develops, manufactures, and sells molecular imaging agents — fluorescent probes, radiopharmaceuticals, lipophilic dyes, and phosphatidylserine- and phosphatidylethanolamine-targeting compounds — to biomedical researchers. Its portfolio is organized around branded platforms: CellVue® (fluorescent cell membrane labeling kits, licensed-in technology), NeuroVue® (lipophilic far-red filter-based dyes for neural tract tracing, licensed from PTI Research), PSVue® (Zn-DPA–based anionic membrane probes), SRfluor® 680 (squaraine rotaxane dyes), and complementary lines including Lipophilic Cyanines, Immobilized Steroid Beads for affinity chromatography, Duramycin-based apoptosis probes with Kd of 4–6 nM, cyclic RGD and 2-DG optical imaging agents, and Glucarate-Kit/OsteoVue radiopharmaceutical precursors.

The company distributes most products directly through an e-commerce storefront at mtarget.com to academic laboratories, research institutions, and biotechnology and pharmaceutical companies, with unit pricing generally between $250 and $700 and quote-based pricing for custom chemistry services. Approximately 1–10 employees operate from a single West Chester office. MTTI holds exclusive license and sublicense rights to the NeuroVue® and CellVue® brands and several patents covering core chemistries. Leadership includes CEO Dr. Chris Pak (former Centocor/J&J radiopharmaceutical inventor, 20 prior IND filings) and CMO Dr. Danielle Meyrick (radiotheranostics executive with prior CMO roles at ITM Oncologic, Telix Pharmaceuticals, AdvanCell, and GenesisCare CRO). The firm has additionally launched the EvaThera sub-brand (EvaThera.com) to extend toward clinical-stage imaging agents and presented clinical data on the PRRT candidate EBTATE at SNMMI 2026, signaling a strategic move beyond catalog reagents.

Revenue is generated primarily through one-time catalog purchases of research reagents and contract-based custom synthesis services, with no disclosed institutional funding or revenue figures. MTTI has received regional recognition including 2019 Ernst & Young Entrepreneur of the Year finalist status (Greater Philadelphia) and a Ben Franklin Emerging Business Award.

Molecular Targeting Technologies firmographics

Firmographics
Name
Molecular Targeting Technologies
Legal name
Molecular Targeting Technologies, Inc.
Website
https://mtarget.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
Molecular Targeting Technologies is a privately held specialty life-sciences reagent company that develops and sells fluorescent probes, lipophilic dyes, radiopharmaceutical precursors, and imaging agents (CellVue®, NeuroVue®, PSVue®, SRfluor®, Duramycin products) to academic researchers and biotechnology companies through its mtarget.com e-commerce storefront and custom chemistry services.
Ownership category
akta.pro rank

Molecular Targeting Technologies industry classification

Industry
Product category
Life Sciences Research Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Fluorescent imaging probes
  • Molecular imaging reagents
  • Radiopharmaceutical agents
  • Cell labeling dyes
  • Bioconjugation reagents

Where Molecular Targeting Technologies is headquartered

Location

Headquarters

HQ city
West Chester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Molecular Targeting Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Research Products Sales: MTTI generates revenue through direct sales of fluorescent probes, imaging agents, cell membrane labels, and related biochemical products to research institutions, academic laboratories, and biotechnology companies. Products are sold through an e-commerce platform with pricing ranging from approximately $250 to $700 per unit depending on the product type and size.
  2. Custom Chemistry Services: The company offers custom synthesis and chemistry services for specialized research needs, including custom affinity absorbents for chromatography, ligand affinity binding studies, and protein-ligand complexes for crystallography.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Research Products
OtherMulti-year contractCustom Services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Molecular Targeting Technologies product offering

Product offering

Core offering

Molecular Targeting Technologies (MTTI) develops, manufactures, and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for life sciences research. Its catalog spans branded product lines such as CellVue® (cell membrane labels), NeuroVue® (neural tract tracing dyes), PSVue® (phosphatidylserine-targeting probes), SRfluor® (squaraine rotaxane dyes), duramycin-based phosphatidylethanolamine probes, cyclic RGD peptides, radiopharmaceutical cold kits, and immobilized steroid beads, alongside custom chemistry services for specialized reagent synthesis.

Product overview

Molecular Targeting Technologies is a life sciences reagent company that develops and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for research applications. The product portfolio includes branded product lines: CellVue® (cell membrane labeling kits), NeuroVue® (neural tract tracing dyes), PSVue® (anionic membrane-targeting fluorescent probes), and SRfluor® 680 (squaraine rotaxane dyes), alongside complementary product families of Lipophilic Cyanines, Immobilized Steroid Beads, Duramycin-based apoptosis labels, Optical Imaging Agents (including cyclic RGD peptides and cancer-targeting agents), Click Chemistry Reagents, Crosslinkers, and Dyes for Bioconjugation. The company also offers Custom Chemistry Services for specialized synthesis. These products serve researchers in molecular imaging, cell biology, neuroscience, and drug discovery applications.

Differentiator

Problem solved

Functional benefit

Brands

  • CellVue®: Fluorescent cell membrane labeling kits for tracking cell division and membrane staining
  • NeuroVue®
  • PSVue®
  • SRfluor®
  • EvaThera

Products and services

  • CellVue® Fluorescent cell membrane labeling kits that stably label lipid regions of cell membranes; available in multiple spectral variants (Maroon, Claret, Plum, Burgundy, Lavender, Lilac, Red, Jade, NIR780, NIR815) for cell tracking and membrane staining research.
  • NeuroVue® Lipophilic far-red emitting filter-based dyes for neural tract tracing studies; available in Maroon, Red, Orange, Burgundy, Jade, and Red Plus variants with tract tracing durations spanning 3 days to 3-4 weeks. Licensed from PTI Research, Inc.
  • PSVue® Fluorescent probes with Zn-DPA targeting moiety that bind anionic membranes, including phosphatidylserine-targeting variants for apoptosis and microbial detection. Available in PSVue 380, 480, 550, 643, 794, Biotin, Control, and 499-WS (mSEEK) formulations.
  • Lipophilic Cyanines DiI and DiO series of lipophilic carbocyanine dyes for cell membrane staining, available in various alkyl chain lengths (C2 to C28) with spectral properties spanning excitation/emission from 480/499nm to 748/780nm.
  • Immobilized Steroid Beads Sepharose 4FF beads with immobilized steroid ligands (Estradiol, Nortestosterone, Dexamethasone, Androstan, Long Spacer Arm Dexamethasone, and custom options) for affinity chromatography, ligand binding studies, and protein-ligand complex crystallization.
  • Duramycin Products Phosphatidylethanolamine (PE) binding agents including Duramycin and fluorescent conjugates (Cy3, Cy5, Cy7, Fluorescein, LC-Fluorescein, LC-Biotin, NODAGA). Duramycin binds PE with Kd of 4-6 nM at 1:1 ratio with exclusive specificity; NODAGA conjugate supports Ga-68 and Cu-64 radiolabeling for PET imaging.
  • Optical Imaging Agents Fluorescence imaging agents including cyclic RGD peptides for integrin targeting (CyAL-5 cRGD, Cy3 cRGD, cRGD-LC-fluorescein), CyAL-5 2-Deoxyglucose for cancer targeting, and Tracer-653 for vascular imaging.
  • SRfluor® 680 Lipophilic squaraine rotaxane far-red emitting dyes that accumulate at lipophilic sites inside living cells; available in Phenyl, azide, and Micellar Phenyl formulations for in vitro and in vivo applications.
  • Click Chemistry Reagents Reagents for click chemistry reactions including crosslinkers used for bioconjugation and labeling applications.
  • Crosslinkers Heterobifunctional linkers such as SANH (Succinimidyl 6-hydrazinonicotinate acetone hydrazone) used to introduce protected hydrazinonicotinimide functional groups into proteins, peptides, and surfaces.
  • Dyes for Bioconjugation

Quantifiable outcome

  • 99mTc-glucarate cold kit formulation for radiopharmaceutical preparation
  • +1 more outcomes

Companies that use Molecular Targeting Technologies

Customer profile

Segments3 records

Ideal customer profiles3 records

Molecular Targeting Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Molecular Targeting Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • PTI Research, Inc.coreOEM/ Whitelabel/ Licensing PartnerMTTI operates under license and sublicense agreements with PTI Research, Inc. for NeuroVue® and CellVue® products. These are core product lines for the company. The NeuroVue® brand is a trademark of PTI Research used under license, and CellVue® products are sold under sublicense from PTI Research, Inc.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Molecular Targeting Technologies competitors and assessment

Company assessment

Direct peers

  • Click Chemistry Tools: Click Chemistry Tools sells heterobifunctional crosslinkers, click chemistry reagents, and bioconjugation dyes — directly overlapping with MTTI's Crosslinkers (SANH) and Dyes for Bioconjugation categories, and addressing the same research customer.
  • LI-COR Biosciences: LI-COR is well known for IRDye infrared fluorescent dyes used in Western blots, microscopy, and in vivo imaging. Its IRDye platform competes directly with MTTI's NIR fluorescent probes (NIR780, NIR815) for near-infrared imaging research applications.
  • Biotium: Biotium develops fluorescent probes and dyes for cell biology, neuroscience, and live-cell imaging — including membrane, nuclear, and organelle stains. The product overlap with CellVue®, PSVue®, and SRfluor® is tight, especially in fluorescent cell labeling kits sold via e-commerce.
  • Vector Laboratories: Vector Laboratories develops labeling and detection reagents (immunohistochemistry, immunofluorescence, biotin-streptavidin systems) for research and clinical use. Its labeling reagent portfolio complements MTTI's Dyes for Bioconjugation and PSVue® Biotin products.
  • ATTO-Tec GmbH: ATTO-Tec specializes in high-performance fluorescent labels (ATTO series) used in microscopy, flow cytometry, and single-molecule imaging. Their labeling chemistries and spectral breadth directly compete with MTTI's lipophilic cyanines and CellVue® spectral variants.
  • AnaSpec / Eurogentec (Fujifilm): AnaSpec provides fluorescent peptides, custom peptide synthesis, and bioconjugation reagents — overlapping with MTTI's Custom Chemistry Services and Cyclic RGD Imaging Agents. Their custom synthesis offering is the most directly comparable service business.
  • Cytodiagnostics: Cytodiagnostics manufactures lipid-based and gold nanoparticle imaging/labeling reagents including DiI/DiO analogs and custom surface functionalization. Its lipid membrane probe range directly competes with MTTI's Lipophilic Cyanines and PSVue® anionic membrane probes.
  • Lumiprobe Corporation: Lumiprobe manufactures and sells a broad catalog of fluorescent dyes and labeling reagents for biomedical research, including cyanines, NHS esters, and specialty imaging probes. Its catalog scope and direct e-commerce model mirror MTTI's research products business most directly.

Broad incumbents

  • Thermo Fisher Scientific (Molecular Probes / Invitrogen): Thermo Fisher's Molecular Probes / Invitrogen catalog is the gold-standard research fluorescent reagent brand, offering membrane stains, nuclear stains, and labeling kits across the same research applications MTTI targets. It represents the dominant competitive force in catalog research fluorescent reagents.
  • PerkinElmer / Revvity: Revvity (formerly PerkinElmer Life Sciences) is a broad incumbent offering fluorescent imaging agents, radiopharmaceuticals, and preclinical imaging reagents through its Life Sciences portfolio. It competes with MTTI in optical imaging agents and radiopharmaceutical chemistry with much broader geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Molecular Targeting Technologies social profiles

Digital presence

Molecular Targeting Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Targeting Technologies leadership team

Management profile

Number of profiles

Profiles2 records

Molecular Targeting Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Targeting Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Targeting Technologies

What does Molecular Targeting Technologies do?

Molecular Targeting Technologies (MTTI) develops, manufactures, and sells fluorescent labeling reagents, imaging agents, and affinity chromatography products for life sciences research. Its catalog spans branded product lines such as CellVue® (cell membrane labels), NeuroVue® (neural tract tracing dyes), PSVue® (phosphatidylserine-targeting probes), SRfluor® (squaraine rotaxane dyes), duramycin-based phosphatidylethanolamine probes, cyclic RGD peptides, radiopharmaceutical cold kits, and immobilized steroid beads, alongside custom chemistry services for specialized reagent synthesis.

Is Molecular Targeting Technologies a public or private company?

Molecular Targeting Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Molecular Targeting Technologies founded?

Molecular Targeting Technologies was founded in 2012. It employs 1 to 10 people.

Where is Molecular Targeting Technologies based?

Molecular Targeting Technologies is headquartered in West Chester, United States, in the North America region.

How does Molecular Targeting Technologies make money?

Two revenue lines are on record. Research Products Sales are the primary driver. The others are custom Chemistry Services.

Who are Molecular Targeting Technologies's main competitors?

Direct peers on record are Click Chemistry Tools, LI-COR Biosciences, Biotium, Vector Laboratories, ATTO-Tec GmbH, AnaSpec / Eurogentec (Fujifilm), Cytodiagnostics and Lumiprobe Corporation. Broad incumbents are Thermo Fisher Scientific (Molecular Probes / Invitrogen) and PerkinElmer / Revvity.

Does Molecular Targeting Technologies have an API?

No public API is recorded for Molecular Targeting Technologies.

What industry is Molecular Targeting Technologies in?

Molecular Targeting Technologies's product category is Life Sciences Research Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0MTTI Awarded $3.17 Million NCI Grant To Advance Lu-177-EBRGD For Non-Small Cell Lung CancerMolecular Targeting Technologies received a $3.17 million, five-year NCI grant to advance Lu-177-EBRGD, an integrin αvβ3-targeting radiopharmaceutical for non-small cell lung cancer. The award supports preclinical research, manufacturing, and clinical study planning. The company aims to progress toward clinical evaluation for metastatic NSCLC patients.BioSpaceMTTI Awarded $3.17 Million NCI Grant to Advance ¹⁷⁷Lu-EBRGD Development for Non-Small Cell Lung CancerMolecular Targeting Technologies, Inc. received a $3.17 million, five-year NCI grant to advance ¹⁷⁷Lu-EBRGD, an integrin αvβ3-targeted radiopharmaceutical for non-small cell lung cancer. The award supports preclinical research, manufacturing, regulatory preparation, and planned clinical studies. The company aims to evaluate the drug's therapeutic potential in patients with metastatic NSCLC.FinSMEsMolecular Targeting Technologies Receives $3.17M NCI GrantMolecular Targeting Technologies received a $3.17M, five-year NCI grant to advance ¹⁷⁷Lu-EBRGD, an integrin αvβ3-targeted radiopharmaceutical for non-small cell lung cancer. The award supports preclinical research, manufacturing, regulatory preparation, and planned clinical studies. The program builds on the company's EvaThera platform.FinancialContent Business PageMolecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™Molecular Targeting Technologies received Pharma Tech Outlook's 2026 Radiopharmaceutical Therapy Solution of the Year for its EvaThera platform. Clinical data for 177Lu-EBTATE showed up to 15 days of tumor retention and eight-fold higher uptake versus DOTA-TATE. The company is advancing the platform across multiple targets and radionuclides.MorningstarMolecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™Molecular Targeting Technologies received Pharma Tech Outlook's 2026 Radiopharmaceutical Therapy Solution of the Year for its EvaThera platform. Clinical data on 177Lu-EBTATE showed up to 35-fold greater tumor uptake and retention versus a control, with a two-cycle regimen using 12.5% of the activity of a four-cycle regimen. The company is seeking licensing and co-development opportunities.Business Wire BlogMolecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™Molecular Targeting Technologies received Pharma Tech Outlook's 2026 Radiopharmaceutical Therapy Solution of the Year for its EvaThera platform. Clinical data on 177Lu-EBTATE showed up to 35-fold greater tumor uptake and retention versus a control, with a two-cycle regimen using 12.5% of the activity of a four-cycle regimen. The company is seeking licensing and co-development opportunities.BioSpaceMolecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026Molecular Targeting Technologies presented clinical data on its ¹⁷⁷Lu-DOTA-EB-TATE PRRT at SNMMI 2026, showing higher tumor uptake and prolonged retention than ¹⁷⁷Lu-DOTATATE. The data support a two-cycle regimen delivering about 12.5% of cumulative radioactivity with no kidney toxicity after one year.Business Wire BlogMTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing SummitMolecular Targeting Technologies, Inc. will present a workshop on evaluating radioisotope commercial viability at the 2nd TRP Supply Chain & Manufacturing Summit in Boston on September 24-26, 2024. The company's EB platform delivers 8-30-fold more target uptake with 40% of the radiation dose, according to CEO Chris Pak.Business Wire BlogITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177ITM Isotope Technologies and Molecular Targeting Technologies signed a global clinical supply agreement for n.c.a. lutetium-177 to support MTTI's radiopharmaceutical candidate n.c.a. 177Lu-EBTATE. The agreement covers preclinical and clinical development and potential commercial production for treating neuroendocrine tumors, thyroid cancer, and nasopharyngeal cancer.PR NewswireIsotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for Lu177 n.c.a.Isotopia Molecular Imaging has signed a clinical supply agreement with Molecular Targeting Technologies, Inc. (MTTI) to supply no-carrier-added 177Lu (n.c.a. 177Lu) for clinical development of MTTI's targeted radiotherapeutic products. MTTI will use the radioisotope for its lead candidate 177Lu-EBTATE targeting neuroendocrine tumors and 177Lu-EBRGD for glioblastoma and non-small cell lung cancer. The agreement provides MTTI with a sustainable supply of a key therapeutic ingredient needed for development and launch of its EB platform technologies.